InsidersTradesSigma
Total declarations
Company
▲ Purchases (9 ops.)
▼ Sales (0 ops.)
Browse the complete record of transactions filed by Schuetz Thomas J., Chairman & CEO. Officer active across 1 companies, notably Compass Therapeutics, Inc.. Cumulatively, 11 disclosures have been published. Total volume traded: €498k. The latest transaction was filed on 21 June 2022 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations11 total
€53,16820,000 shares@ €2.65840.016% mcap10.7% of flow
Common Stock
SEC:0001171843-22-004440:0·
Ideal exit: 18 Mar 2023 (T+270)
€44,37320,000 shares@ €2.21870.013% mcap8.9% of flow
Common Stock
SEC:0001171843-22-004408:0·
Ideal exit: 13 Mar 2023 (T+270)
€65,96230,000 shares@ €2.19870.020% mcap13.2% of flow
Common Stock
SEC:0001171843-22-004327:0·
Ideal exit: 10 Mar 2023 (T+270)
€79,41030,000 shares@ €2.6470.024% mcap15.9% of flow
Common Stock
SEC:0001171843-22-004190:0·
Ideal exit: 3 Mar 2023 (T+270)
€56,87920,000 shares@ €2.8440.017% mcap11.4% of flow
Common Stock
SEC:0001171843-22-004068:0·
Ideal exit: 26 Feb 2023 (T+270)
€56,64820,000 shares@ €2.83240.017% mcap11.4% of flow
Common Stock
SEC:0001171843-22-003978:0·
Ideal exit: 20 Feb 2023 (T+270)
€46,73818,355 shares@ €2.54630.014% mcap9.4% of flow
Common Stock
SEC:0001171843-22-003899:0·
Ideal exit: 17 Feb 2023 (T+270)
€47,33820,215 shares@ €2.34170.014% mcap9.5% of flow
Common Stock
SEC:0001171843-22-003771:0·
Ideal exit: 11 Feb 2023 (T+270)
€47,56927,836 shares@ €1.70890.014% mcap9.6% of flow
Common Stock
SEC:0001171843-22-003503:0·
Ideal exit: 4 Feb 2023 (T+270)
0600,000 shares0
Common Stock
SEC:0000899243-21-045310·
0600,000 shares0
Common Stock
SEC:0000899243-21-045310:0·
11 of 11 declarations
About Schuetz Thomas J.
Thomas J. Schuetz is Chief Executive Officer of Compass Therapeutics, Inc. He leads the company with a strategic vision, focusing on innovation and growth. His leadership is essential to achieving the company's objectives and strengthening its market position.
